Eli Lilly and Company (NEO:LLY)

Market Cap	1.03T
Revenue (ttm)	64.81B
Net Income (ttm)	15.24B
Shares Out	n/a
EPS (ttm)	16.85
PE Ratio	67.80
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	33,585
Average Volume	48,407
Open	30.96
Previous Close	30.52
Day's Range	30.28 - 31.18
52-Week Range	25.15 - 36.42
Beta	0.50
RSI	55.48
Earnings Date	May 1, 2025

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals in the United States, Europe, China, Japan, and internationally. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Ja...

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• Founded: 1876
• Employees: 47,000
• Stock Exchange: Cboe Canada
• Ticker Symbol: LLY

Financial Performance

In 2024, Eli Lilly and Company's revenue was $45.04 billion, an increase of 32.00% compared to the previous year's $34.12 billion. Earnings were $10.59 billion, an increase of 102.08%.

Financial numbers in USD